SCHEMBL18095490

SCHEMBL18095490

CC(=O)c1cccc(CCCOS(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.46
CYP4A11 Q02928 3/20 0.46
MAOB P27338 5/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
HPGD P15428 2/20 0.40
RAB9A P51151 1/20 0.40
MAOA P21397 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
MMP9 P14780 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18095387 0.92 CYP4F2 (0.42) CYP4F2CYP4A11MAOBALDH1A1SMN1; SMN2
SCHEMBL5464169 0.89 FOLH1 (0.47) CYP4F2CYP4A11SMN1; SMN2RAB9AMRGPRX4
SCHEMBL14415230 0.83 SLC7A5 (0.51) CYP4F2CYP4A11
SCHEMBL18095522 0.83 MAOB (0.42) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL18105872 0.81 MAOB (0.45) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL18105875 0.81 MAOB (0.45) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL18105874 0.81 MAOB (0.45) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL18105880 0.81 MAOB (0.45) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL18095210 0.81 MAOB (0.45) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4278421 0.81 CYP3A4 (0.45) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107567442-B Inhibitors of hepatitis C virus polymerase 共晶制药公司 2021-05-25 CN disclosed
US-10947210-B2 Inhibitors of Hepatitis C virus polymerase COCRYSTAL PHARMA, INC. (US) 2021-03-16 US disclosed
US-20200255393-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. 2020-08-13 US disclosed
US-10464914-B2 Inhibitors of hepatitis C virus polymerase COCRYSTAL PHARMA, INC. (US) 2019-11-05 US disclosed
EP-3274340-B1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA INC (US) 2019-07-17 EP disclosed
US-20180050998-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. 2018-02-22 US disclosed
EP-3274340-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE Cocrystal Pharma, Inc. (US) 2018-01-31 EP disclosed
WO-2016154241-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. (US) 2016-09-29 WO disclosed
WO-2016154241-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL PHARMA, INC. (US) 2016-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255393-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE POLI, POLR2E, POLR2H CYP4F2 803/4885CYP4A11 354/4885MAOB 248/4885
US-10464914-B2 Inhibitors of hepatitis C virus polymerase POLI, POLR2E, POLR2H CYP4F2 803/4885CYP4A11 354/4885MAOB 248/4885
US-10947210-B2 Inhibitors of Hepatitis C virus polymerase POLI, POLR2E, POLR2H CYP4F2 803/4885CYP4A11 354/4885MAOB 248/4885
US-20180050998-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE POLI, POLR2E, POLR2H CYP4F2 803/4885CYP4A11 354/4885MAOB 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.